Tag: LivaNova

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced preliminary unaudited revenue results for the quarter ended March 31, 2019.

Preliminary First Quarter 2019 Results The Company expects worldwide sales from continuing operations for the first quarter 2019 to be approximately $251 million, flat on a reported basis and an increase of 4.0 percent on a constant-currency basis compared to the first quarter of 2018. Neuromodulation sales are anticipated to […]

LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device. Under the terms of the agreement and subject to certain conditions, including acceptance of the settlement by […]

LivaNova Announces Availability of Safety and Technical Information for Valve-in-Valve Procedures on Perceval Platform

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve (ViV) procedures, it has added new safety and technical information to the Perceval U.S. Instructions For Use (IFUs). This addition was made following completion of the Company’s application to the U.S. Food […]

LivaNova’s Perceval Sutureless Aortic Heart Valve Receives National Reimbursement in Japan to Treat Patients with Aortic Valve Disease

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval® sutureless aortic heart valve to treat aortic valve disease. By adding Perceval into Japan’s health insurance system, physicians and patients have greater access to this […]

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the publication of three separate studies highlighting the unique performance of its sutureless aortic valve, Perceval®. The results from the Perceval Aortic Heart Valve Study in North America, performed under a U.S. Food and Drug Administration (FDA) Investigational Device […]

LivaNova Reports Third Quarter 2018 Results

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2018. For the third quarter of 2018, worldwide sales from continuing operations were $272.1 million, an increase of 8.3 percent on a reported basis and an increase of 10.3 percent on […]

LivaNova to Present at the Stifel 2018 Healthcare Conference

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Damien McDonald, Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference on Tuesday, Nov. 13 in New York at 9:30 a.m. Eastern Standard Time. The discussion will be available to all interested parties through a live […]

LivaNova Launches International Pivotal Study Evaluating Use of Autonomic Regulation Therapy for Heart Failure

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the first successful implantation of the VITARIA® System in a patient enrolled in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study. The study is an international, multi-center, randomized trial to evaluate the VITARIA System for the […]